csirt@kutim:~/threat-intel/cve/CVE-2025-22614

Katalog CVE

CVSS 5.4 · Medium EPSS 0,28%

Kerentanan Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') pada wegia. Skor CVSS 3.1 5.4 (Medium) menurut NVD.

Deskripsi (NVD)

WeGIA is an open source web manager with a focus on the Portuguese language and charitable institutions. A Stored Cross-Site Scripting (XSS) vulnerability was identified in the `dependente_editarInfoPessoal.php` endpoint of the WeGIA application. This vulnerability allows attackers to inject malicious scripts into the `nome` and `SobrenomeForm`parameters. The injected scripts are stored on the server and executed automatically whenever the affected page is accessed by users, posing a significant security risk. The application fails to properly validate and sanitize user inputs in the `dependente_editarInfoPessoal.php` parameters. This lack of validation allows attackers to inject malicious scripts, which are then stored on the server. Whenever the affected page is accessed, the malicious payload is executed in the victim's browser, potentially compromising the user's data and system. This issue has been addressed in version 3.2.6 and all users are advised to upgrade. There are no known workarounds for this vulnerability.

Rincian

Terbit di NVD
13 Januari 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
5.4 (Medium), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:N · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-79: Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting')
EPSS (30 hari)
0,28% peluang dieksploitasi; lebih tinggi dari 19,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
wegia wegia Semua versi sebelum 3.2.6

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.